Stay ahead of the curve with Biomedtracker’s 2025 Pre-ASCO Report, your essential guide to the most impactful abstracts from this year’s American Society of Clinical Oncology (ASCO) Annual Meeting. This comprehensive report delivers objective information alongside evidence-based analysis on the latest clinical developments shaping the future of oncology.
Share:
Stay ahead of the curve with Biomedtracker’s 2025 Pre-ASCO Report, your essential guide to the most impactful abstracts from this year’s American Society of Clinical Oncology (ASCO) Annual Meeting. This comprehensive report delivers objective information alongside evidence-based analysis on the latest clinical developments shaping the future of oncology.
Western pharma committed close to $2 billion in licensing deals and acquisitions for China-originated assets in Q1 2026 alone.
